Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ERIBULIN for Breast cancer metastatic: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 1,152 adverse event reports in the FDA FAERS database where ERIBULIN was used for Breast cancer metastatic.

Most Reported Side Effects for ERIBULIN

Side Effect Reports % Deaths Hosp.
Neutropenia 675 13.4% 112 289
Malignant neoplasm progression 594 11.8% 228 158
Myelosuppression 520 10.3% 2 380
Febrile neutropenia 448 8.9% 65 378
Neutrophil count decreased 294 5.8% 14 159
Neuropathy peripheral 290 5.7% 44 124
White blood cell count decreased 289 5.7% 10 146
Pyrexia 275 5.4% 66 218
Disease progression 211 4.2% 67 53
Fatigue 209 4.1% 72 111
Anaemia 188 3.7% 29 108
Leukopenia 185 3.7% 51 103
Nausea 183 3.6% 48 102
Interstitial lung disease 171 3.4% 30 91
Thrombocytopenia 168 3.3% 55 87

Other Indications for ERIBULIN

Breast cancer (1,736) Product used for unknown indication (355) Breast cancer recurrent (346) Triple negative breast cancer (171) Invasive ductal breast carcinoma (127) Her2 positive breast cancer (108) Soft tissue sarcoma (66) Breast cancer stage iv (58) Chemotherapy (52) Her-2 positive breast cancer (50)

Other Drugs Used for Breast cancer metastatic

PALBOCICLIB (18,160) RIBOCICLIB (9,771) LETROZOLE (6,856) TRASTUZUMAB (6,303) FULVESTRANT (4,570) PERTUZUMAB (3,784) CAPECITABINE (3,691) PACLITAXEL (3,241) DOCETAXEL (3,070) EVEROLIMUS (2,751)

Related Pages

ERIBULIN Full Profile All Breast cancer metastatic Drugs ERIBULIN Demographics ERIBULIN Timeline